Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.

Slon-Campos JL, Dejnirattisai W, Jagger BW, López-Camacho C, Wongwiwat W, Durnell LA, Winkler ES, Chen RE, Reyes-Sandoval A, Rey FA, Diamond MS, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2019 Oct;20(10):1291-1298. doi: 10.1038/s41590-019-0477-z. Epub 2019 Sep 2.

2.

Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.

Salazar V, Jagger BW, Mongkolsapaya J, Burgomaster KE, Dejnirattisai W, Winkler ES, Fernandez E, Nelson CA, Fremont DH, Pierson TC, Crowe JE Jr, Screaton GR, Diamond MS.

Cell Rep. 2019 Feb 5;26(6):1585-1597.e4. doi: 10.1016/j.celrep.2019.01.052.

3.

The immune response against flaviviruses.

Slon Campos JL, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2018 Nov;19(11):1189-1198. doi: 10.1038/s41590-018-0210-3. Epub 2018 Oct 17. Review.

PMID:
30333606
4.

Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.

Renner M, Flanagan A, Dejnirattisai W, Puttikhunt C, Kasinrerk W, Supasa P, Wongwiwat W, Chawansuntati K, Duangchinda T, Cowper A, Midgley CM, Malasit P, Huiskonen JT, Mongkolsapaya J, Screaton GR, Grimes JM.

Nat Immunol. 2018 Nov;19(11):1248-1256. doi: 10.1038/s41590-018-0227-7. Epub 2018 Oct 15.

PMID:
30323338
5.

Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0.

Bidmos FA, Nadel S, Screaton GR, Kroll JS, Langford PR.

Front Immunol. 2018 Jul 16;9:1621. doi: 10.3389/fimmu.2018.01621. eCollection 2018.

6.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.

López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A.

Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.

7.

Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys.

Abbink P, Larocca RA, Dejnirattisai W, Peterson R, Nkolola JP, Borducchi EN, Supasa P, Mongkolsapaya J, Screaton GR, Barouch DH.

Nat Med. 2018 Jun;24(6):721-723. doi: 10.1038/s41591-018-0056-0. Epub 2018 Jun 4.

8.

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.

Fernandez E, Dejnirattisai W, Cao B, Scheaffer SM, Supasa P, Wongwiwat W, Esakky P, Drury A, Mongkolsapaya J, Moley KH, Mysorekar IU, Screaton GR, Diamond MS.

Nat Immunol. 2017 Nov;18(11):1261-1269. doi: 10.1038/ni.3849. Epub 2017 Sep 25.

9.

Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.

Culshaw A, Ladell K, Gras S, McLaren JE, Miners KL, Farenc C, van den Heuvel H, Gostick E, Dejnirattisai W, Wangteeraprasert A, Duangchinda T, Chotiyarnwong P, Limpitikul W, Vasanawathana S, Malasit P, Dong T, Rossjohn J, Mongkolsapaya J, Price DA, Screaton GR.

Nat Immunol. 2017 Nov;18(11):1228-1237. doi: 10.1038/ni.3850. Epub 2017 Sep 25.

10.

The immunopathology of dengue and Zika virus infections.

Culshaw A, Mongkolsapaya J, Screaton GR.

Curr Opin Immunol. 2017 Oct;48:1-6. doi: 10.1016/j.coi.2017.07.001. Epub 2017 Jul 21. Review.

11.

Cardio-haemodynamic assessment and venous lactate in severe dengue: Relationship with recurrent shock and respiratory distress.

Yacoub S, Trung TH, Lam PK, Thien VHN, Hai DHT, Phan TQ, Nguyet OPK, Quyen NTH, Simmons CP, Broyd C, Screaton GR, Wills B.

PLoS Negl Trop Dis. 2017 Jul 10;11(7):e0005740. doi: 10.1371/journal.pntd.0005740. eCollection 2017 Jul.

12.

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope.

Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney MC, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, Mongkolsapaya J, Rey FA, Screaton GR.

Nat Commun. 2017 May 23;8:15411. doi: 10.1038/ncomms15411.

13.

Antibodies and tuberculosis.

Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ.

Tuberculosis (Edinb). 2016 Dec;101:102-113. doi: 10.1016/j.tube.2016.08.001. Epub 2016 Aug 26. Review.

14.

Erratum: Structural basis of potent Zika-dengue virus antibody cross-neutralization.

Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Lorière E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA.

Nature. 2016 Nov 10;539(7628):314. doi: 10.1038/nature19780. Epub 2016 Sep 14. No abstract available.

PMID:
27626374
15.

Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes.

Lebre MC, Vieira PL, Tang MW, Aarrass S, Helder B, Newsom-Davis T, Tak PP, Screaton GR.

J Leukoc Biol. 2017 Mar;101(3):775-783. doi: 10.1189/jlb.5A0516-217RR. Epub 2016 Oct 12.

PMID:
27733582
16.

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.

Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2016 Sep;17(9):1102-8. doi: 10.1038/ni.3515. Epub 2016 Jun 23.

17.

Structural basis of potent Zika-dengue virus antibody cross-neutralization.

Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Lorière E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA.

Nature. 2016 Aug 4;536(7614):48-53. doi: 10.1038/nature18938. Epub 2016 Jun 23. Erratum in: Nature. 2016 Nov 10;539(7628):314.

18.

MAIT cells are activated during human viral infections.

van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de Lara C, Cole S, Vasanawathana S, Limpitikul W, Malasit P, Young D, Denney L; STOP-HCV consortium, Moore MD, Fabris P, Giordani MT, Oo YH, Laidlaw SM, Dustin LB, Ho LP, Thompson FM, Ramamurthy N, Mongkolsapaya J, Willberg CB, Screaton GR, Klenerman P.

Nat Commun. 2016 Jun 23;7:11653. doi: 10.1038/ncomms11653.

19.

Association of Microvascular Function and Endothelial Biomarkers With Clinical Outcome in Dengue: An Observational Study.

Yacoub S, Lam PK, Vu le HM, Le TL, Ha NT, Toan TT, Van NT, Quyen NT, Le Duyen HT, Van Kinh N, Fox A, Mongkolspaya J, Wolbers M, Simmons CP, Screaton GR, Wertheim H, Wills B.

J Infect Dis. 2016 Sep 1;214(5):697-706. doi: 10.1093/infdis/jiw220. Epub 2016 May 26.

20.

Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions.

Jönsson P, Southcombe JH, Santos AM, Huo J, Fernandes RA, McColl J, Lever M, Evans EJ, Hudson A, Chang VT, Hanke T, Godkin A, Dunne PD, Horrocks MH, Palayret M, Screaton GR, Petersen J, Rossjohn J, Fugger L, Dushek O, Xu XN, Davis SJ, Klenerman D.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):5682-7. doi: 10.1073/pnas.1513918113. Epub 2016 Apr 25.

21.

Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2015 Jul;16(7):785. doi: 10.1038/ni0715-785a. No abstract available.

PMID:
26086146
22.

Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2015 May;16(5):544. doi: 10.1038/ni0515-544b. No abstract available.

PMID:
25898199
23.

Recognition determinants of broadly neutralizing human antibodies against dengue viruses.

Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Desprès P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA.

Nature. 2015 Apr 2;520(7545):109-13. doi: 10.1038/nature14130. Epub 2015 Jan 12.

24.

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR.

Nat Immunol. 2015 Feb;16(2):170-177. doi: 10.1038/ni.3058. Epub 2014 Dec 15. Erratum in: Nat Immunol. 2015 May;16(5):544. Nat Immunol. 2015 Jul;16(7):785.

25.

Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.

Décembre E, Assil S, Hillaire ML, Dejnirattisai W, Mongkolsapaya J, Screaton GR, Davidson AD, Dreux M.

PLoS Pathog. 2014 Oct 23;10(10):e1004434. doi: 10.1371/journal.ppat.1004434. eCollection 2014 Oct.

26.

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK.

J Virol. 2013 Dec;87(23):12562-75. doi: 10.1128/JVI.00871-13. Epub 2013 Sep 11.

27.

Complement alternative pathway genetic variation and Dengue infection in the Thai population.

Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N, Botto M, Screaton GR, Mongkolsapaya J, Pickering MC.

Clin Exp Immunol. 2013 Nov;174(2):326-34. doi: 10.1111/cei.12184.

28.

A novel role of CD1c in regulating CD1d-mediated NKT cell recognition by competitive binding to Ig-like transcript 4.

Li D, Hong A, Lu Q, Gao GF, Jin B, Screaton GR, Xu XN.

Int Immunol. 2012 Nov;24(11):729-37. doi: 10.1093/intimm/dxs082. Epub 2012 Aug 11.

PMID:
22888216
29.

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, Screaton GR.

J Immunol. 2012 May 15;188(10):4971-9. doi: 10.4049/jimmunol.1200227. Epub 2012 Apr 9.

30.

Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling.

Watson AA, Lebedev AA, Hall BA, Fenton-May AE, Vagin AA, Dejnirattisai W, Felce J, Mongkolsapaya J, Palma AS, Liu Y, Feizi T, Screaton GR, Murshudov GN, O'Callaghan CA.

J Biol Chem. 2011 Jul 8;286(27):24208-18. doi: 10.1074/jbc.M111.226142. Epub 2011 May 12.

31.

An in-depth analysis of original antigenic sin in dengue virus infection.

Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, Grimes JM, Yoksan S, Malasit P, Simmons CP, Mongkolsapaya J, Screaton GR.

J Virol. 2011 Jan;85(1):410-21. doi: 10.1128/JVI.01826-10. Epub 2010 Oct 27. Erratum in: J Virol. 2011 Nov;85(22):12100. Chotiyarnwon, Pojchong [corrected to Chotiyarnwong, Pojchong].

32.

The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death.

Freundt EC, Yu L, Goldsmith CS, Welsh S, Cheng A, Yount B, Liu W, Frieman MB, Buchholz UJ, Screaton GR, Lippincott-Schwartz J, Zaki SR, Xu XN, Baric RS, Subbarao K, Lenardo MJ.

J Virol. 2010 Jan;84(2):1097-109. doi: 10.1128/JVI.01662-09. Epub 2009 Nov 4.

33.

Enhanced immune recognition of cryptic glycan markers in human tumors.

Newsom-Davis TE, Wang D, Steinman L, Chen PF, Wang LX, Simon AK, Screaton GR.

Cancer Res. 2009 Mar 1;69(5):2018-25. doi: 10.1158/0008-5472.CAN-08-3589. Epub 2009 Feb 17.

34.

Ig-like transcript 4 inhibits lipid antigen presentation through direct CD1d interaction.

Li D, Wang L, Yu L, Freundt EC, Jin B, Screaton GR, Xu XN.

J Immunol. 2009 Jan 15;182(2):1033-40.

35.

T cell responses to whole SARS coronavirus in humans.

Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin CL, Screaton GR, Hou JL, McMichael AJ, Xu XN.

J Immunol. 2008 Oct 15;181(8):5490-500.

36.

Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.

Simon AK, Newsom-Davis T, Frayne ME, Ch'en PF, McMichael AJ, Screaton GR.

Int Immunol. 2008 Apr;20(4):525-34. doi: 10.1093/intimm/dxn011. Epub 2008 Feb 28.

PMID:
18310066
37.

Generation and characterisation of CD1d tetramer produced by a lentiviral expression system.

Li D, Chen N, McMichael AJ, Screaton GR, Xu XN.

J Immunol Methods. 2008 Jan 31;330(1-2):57-63. Epub 2007 Nov 26.

PMID:
18068183
38.

Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndrome.

Kimberley FC, Lobito AA, Siegel RM, Screaton GR.

Arthritis Res Ther. 2007;9(4):217. Review.

39.

CTLs target Th cells that acquire bystander MHC class I-peptide complex from APCs.

Cox JH, McMichael AJ, Screaton GR, Xu XN.

J Immunol. 2007 Jul 15;179(2):830-6.

40.

Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS).

Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, Kastner DL, Screaton GR, Siegel RM.

Blood. 2006 Aug 15;108(4):1320-7. Epub 2006 May 9.

41.

HIV-1 down-regulates the expression of CD1d via Nef.

Chen N, McCarthy C, Drakesmith H, Li D, Cerundolo V, McMichael AJ, Screaton GR, Xu XN.

Eur J Immunol. 2006 Feb;36(2):278-86.

42.

Characterisation of monoclonal antibodies to the TNF and TNF receptor families.

Ch'en PF, Xu XG, Liu XS, Liu Y, Song CJ, Screaton GR, Jin BQ, Xu XN.

Cell Immunol. 2005 Jul-Aug;236(1-2):78-85. Epub 2005 Sep 12.

PMID:
16157320
43.

Expression of TRAIL and TRAIL receptors in normal and malignant tissues.

Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F, Screaton GR.

Cell Res. 2005 Jun;15(6):430-8.

44.
45.

Following a TRAIL: update on a ligand and its five receptors.

Kimberley FC, Screaton GR.

Cell Res. 2004 Oct;14(5):359-72. Review.

46.
47.

Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies.

Simon AK, Gallimore A, Jones E, Sawitzki B, Cerundolo V, Screaton GR.

Cancer Cell. 2002 Oct;2(4):315-22.

48.

MHC/peptide tetramer-based studies of T cell function.

Xu XN, Screaton GR.

J Immunol Methods. 2002 Oct 1;268(1):21-8. Review.

PMID:
12213339
49.

Virus infections: escape, resistance, and counterattack.

Xu XN, Screaton GR, McMichael AJ.

Immunity. 2001 Dec;15(6):867-70.

50.

Serine-arginine (SR) protein-like factors that antagonize authentic SR proteins and regulate alternative splicing.

Cowper AE, Cáceres JF, Mayeda A, Screaton GR.

J Biol Chem. 2001 Dec 28;276(52):48908-14. Epub 2001 Oct 29.

Supplemental Content

Loading ...
Support Center